Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.
Identifieur interne : 000F95 ( Main/Corpus ); précédent : 000F94; suivant : 000F96Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.
Auteurs : David R. Maguire ; Charles P. FranceSource :
- Behavioural pharmacology [ 1473-5849 ] ; 2016.
English descriptors
- KwdEn :
- Analgesics, Non-Narcotic (therapeutic use), Analysis of Variance (MeSH), Animals (MeSH), Conditioning, Operant (drug effects), Disease Models, Animal (MeSH), Dronabinol (therapeutic use), Female (MeSH), Heroin (administration & dosage), Heroin Dependence (drug therapy), Macaca mulatta (MeSH), Male (MeSH), Narcotics (administration & dosage), Reinforcement, Psychology (MeSH), Self Administration (MeSH).
- MESH :
- chemical , administration & dosage : Heroin, Narcotics.
- chemical , therapeutic use : Analgesics, Non-Narcotic, Dronabinol.
- drug effects : Conditioning, Operant.
- drug therapy : Heroin Dependence.
- Analysis of Variance, Animals, Disease Models, Animal, Female, Macaca mulatta, Male, Reinforcement, Psychology, Self Administration.
Abstract
Opioid abuse remains a significant public health problem; together with the greater availability of marijuana in some regions there is an increasing likelihood that opioids and marijuana will be used together. Polydrug abuse is associated with increased toxicity and poorer treatment outcome; thus, a better understanding of the consequences of repeated coadministration of these drugs will facilitate the development of better prevention and treatment strategies. This study examined the effects of daily treatment with the cannabinoid receptor agonist delta-9-tetrahydrocannabinol (Δ-THC) and its discontinuation on self-administration of heroin in rhesus monkeys (n=4) lever-pressing under a fixed-ratio 30 schedule. Heroin self-administration (0.32-32 μg/kg/infusion, intravenously) generated an inverted U-shaped dose-effect curve. Administered acutely, Δ-THC (0.01-0.32 mg/kg, subcutaneously) dose dependently decreased responding for heroin and flattened the self-administration dose-effect curve. Daily treatment with Δ-THC (0.01-0.1 mg/kg/12 h, subcutaneously) either had no effect on or decreased responding for heroin. In addition, daily treatment did not significantly impact extinction of heroin self-administration or resumption of responding for heroin after extinction. Discontinuation of daily Δ-THC treatment did not systematically impact rates of heroin self-administration. These data suggest that repeated administration of a cannabinoid receptor agonist likely does not increase, and possibly decreases, the positive reinforcing effects of a mu opioid receptor agonist.
DOI: 10.1097/FBP.0000000000000192
PubMed: 26397756
PubMed Central: PMC4779715
Links to Exploration step
pubmed:26397756Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.</title><author><name sortKey="Maguire, David R" sort="Maguire, David R" uniqKey="Maguire D" first="David R" last="Maguire">David R. Maguire</name><affiliation><nlm:affiliation>aDepartment of Pharmacology (DRM, CPF) bDepartment of Psychiatry (CPF), the University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.</nlm:affiliation></affiliation></author><author><name sortKey="France, Charles P" sort="France, Charles P" uniqKey="France C" first="Charles P" last="France">Charles P. France</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26397756</idno><idno type="pmid">26397756</idno><idno type="doi">10.1097/FBP.0000000000000192</idno><idno type="pmc">PMC4779715</idno><idno type="wicri:Area/Main/Corpus">000F95</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.</title><author><name sortKey="Maguire, David R" sort="Maguire, David R" uniqKey="Maguire D" first="David R" last="Maguire">David R. Maguire</name><affiliation><nlm:affiliation>aDepartment of Pharmacology (DRM, CPF) bDepartment of Psychiatry (CPF), the University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.</nlm:affiliation></affiliation></author><author><name sortKey="France, Charles P" sort="France, Charles P" uniqKey="France C" first="Charles P" last="France">Charles P. France</name></author></analytic><series><title level="j">Behavioural pharmacology</title><idno type="eISSN">1473-5849</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analgesics, Non-Narcotic (therapeutic use)</term><term>Analysis of Variance (MeSH)</term><term>Animals (MeSH)</term><term>Conditioning, Operant (drug effects)</term><term>Disease Models, Animal (MeSH)</term><term>Dronabinol (therapeutic use)</term><term>Female (MeSH)</term><term>Heroin (administration & dosage)</term><term>Heroin Dependence (drug therapy)</term><term>Macaca mulatta (MeSH)</term><term>Male (MeSH)</term><term>Narcotics (administration & dosage)</term><term>Reinforcement, Psychology (MeSH)</term><term>Self Administration (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Heroin</term><term>Narcotics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics, Non-Narcotic</term><term>Dronabinol</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Conditioning, Operant</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heroin Dependence</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Macaca mulatta</term><term>Male</term><term>Reinforcement, Psychology</term><term>Self Administration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Opioid abuse remains a significant public health problem; together with the greater availability of marijuana in some regions there is an increasing likelihood that opioids and marijuana will be used together. Polydrug abuse is associated with increased toxicity and poorer treatment outcome; thus, a better understanding of the consequences of repeated coadministration of these drugs will facilitate the development of better prevention and treatment strategies. This study examined the effects of daily treatment with the cannabinoid receptor agonist delta-9-tetrahydrocannabinol (Δ-THC) and its discontinuation on self-administration of heroin in rhesus monkeys (n=4) lever-pressing under a fixed-ratio 30 schedule. Heroin self-administration (0.32-32 μg/kg/infusion, intravenously) generated an inverted U-shaped dose-effect curve. Administered acutely, Δ-THC (0.01-0.32 mg/kg, subcutaneously) dose dependently decreased responding for heroin and flattened the self-administration dose-effect curve. Daily treatment with Δ-THC (0.01-0.1 mg/kg/12 h, subcutaneously) either had no effect on or decreased responding for heroin. In addition, daily treatment did not significantly impact extinction of heroin self-administration or resumption of responding for heroin after extinction. Discontinuation of daily Δ-THC treatment did not systematically impact rates of heroin self-administration. These data suggest that repeated administration of a cannabinoid receptor agonist likely does not increase, and possibly decreases, the positive reinforcing effects of a mu opioid receptor agonist. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26397756</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5849</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2-3 Spec Issue</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Behavioural pharmacology</Title><ISOAbbreviation>Behav Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.</ArticleTitle><Pagination><MedlinePgn>249-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/FBP.0000000000000192</ELocationID><Abstract><AbstractText>Opioid abuse remains a significant public health problem; together with the greater availability of marijuana in some regions there is an increasing likelihood that opioids and marijuana will be used together. Polydrug abuse is associated with increased toxicity and poorer treatment outcome; thus, a better understanding of the consequences of repeated coadministration of these drugs will facilitate the development of better prevention and treatment strategies. This study examined the effects of daily treatment with the cannabinoid receptor agonist delta-9-tetrahydrocannabinol (Δ-THC) and its discontinuation on self-administration of heroin in rhesus monkeys (n=4) lever-pressing under a fixed-ratio 30 schedule. Heroin self-administration (0.32-32 μg/kg/infusion, intravenously) generated an inverted U-shaped dose-effect curve. Administered acutely, Δ-THC (0.01-0.32 mg/kg, subcutaneously) dose dependently decreased responding for heroin and flattened the self-administration dose-effect curve. Daily treatment with Δ-THC (0.01-0.1 mg/kg/12 h, subcutaneously) either had no effect on or decreased responding for heroin. In addition, daily treatment did not significantly impact extinction of heroin self-administration or resumption of responding for heroin after extinction. Discontinuation of daily Δ-THC treatment did not systematically impact rates of heroin self-administration. These data suggest that repeated administration of a cannabinoid receptor agonist likely does not increase, and possibly decreases, the positive reinforcing effects of a mu opioid receptor agonist. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>aDepartment of Pharmacology (DRM, CPF) bDepartment of Psychiatry (CPF), the University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>France</LastName><ForeName>Charles P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K05DA17918</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32DA031115</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K05 DA017918</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 DA035605</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA005018</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA031115</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DA005018</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32DA035605</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Behav Pharmacol</MedlineTA><NlmUniqueID>9013016</NlmUniqueID><ISSNLinking>0955-8810</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009294">Narcotics</NameOfSubstance></Chemical><Chemical><RegistryNumber>70D95007SX</RegistryNumber><NameOfSubstance UI="D003932">Heroin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7J8897W37S</RegistryNumber><NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003932" MajorTopicYN="N">Heroin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006556" MajorTopicYN="N">Heroin Dependence</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009294" MajorTopicYN="N">Narcotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012054" MajorTopicYN="N">Reinforcement, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26397756</ArticleId><ArticleId IdType="doi">10.1097/FBP.0000000000000192</ArticleId><ArticleId IdType="pmc">PMC4779715</ArticleId><ArticleId IdType="mid">NIHMS717866</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychopharmacology (Berl). 1980;71(2):201-2</Citation><ArticleIdList><ArticleId IdType="pubmed">6255508</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacologia. 1972;26(3):297-306</Citation><ArticleIdList><ArticleId IdType="pubmed">5073049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2005 Jun;81(2):360-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15927245</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2005 Sep;16(5-6):363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16148440</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Nov;30(11):2046-57</Citation><ArticleIdList><ArticleId IdType="pubmed">15870833</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2006 Feb 1;81(2):103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16023304</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2006 Feb 28;81(3):293-300</Citation><ArticleIdList><ArticleId IdType="pubmed">16154714</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2007 Jun;32(6):1391-403</Citation><ArticleIdList><ArticleId IdType="pubmed">17091128</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2008 Aug;199(2):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">18470505</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2009 Jun;204(3):403-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19194694</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2010 Feb;10(1):80-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19857996</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2010 Aug;211(2):141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20490465</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2011 Mar;162(5):1060-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21091643</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Pain. 2011 Mar-Apr;27(3):194-202</Citation><ArticleIdList><ArticleId IdType="pubmed">21178601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Feb 24;69(4):650-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21338877</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Physician. 2012 Jul;15(3 Suppl):ES9-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22786464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2012 Sep;342(3):843-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22718500</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2012 Nov 1;126(1-2):65-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22609061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Safety Res. 2012 Sep;43(4):283-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23127678</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2012 Dec;23(8):754-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23044830</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2013 Jan;225(1):173-85</Citation><ArticleIdList><ArticleId IdType="pubmed">22836370</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2013 Jun;345(3):354-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23536317</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2013 Aug 1;131(3):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23294765</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2013 Sep 17;248:637-54</Citation><ArticleIdList><ArticleId IdType="pubmed">23624062</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2000 Jun 1;59(3):251-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10812285</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2000 Jun 1;59(3):261-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10812286</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2001 Mar 23;416(1-2):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11282115</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2001 Nov;158(3):259-66</Citation><ArticleIdList><ArticleId IdType="pubmed">11713615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2002 Aug;95(2):153-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12182962</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Feb;166(1):77-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12491025</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2003 Apr 1;69(3):215-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12633908</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2003 Mar 28;465(1-2):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12650839</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2003 Apr;17(8):1723-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12752390</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Jul;168(1-2):164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12669182</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Sep;169(2):115-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12827346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anal Toxicol. 2004 May-Jun;28(4):217-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15189671</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Aug;29(8):1558-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15173844</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1986 Nov;239(2):311-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3021952</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:26397756
|texte= Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:26397756" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |